On Nov 08, major Wall Street analysts update their ratings for $Tandem Diabetes Care (TNDM.US)$, with price targets ranging from $40 to $75.
Barclays analyst Matt Miksic maintains with a buy rating, and adjusts the target price from $58 to $60.
UBS analyst Danielle Antalffy maintains with a hold rating, and maintains the target price at $40.
TD Cowen analyst Josh Jennings maintains with a buy rating, and maintains the target price at $45.
Stifel analyst Mathew Blackman maintains with a buy rating, and maintains the target price at $60.
RBC Capital analyst Shagun Singh Chadha maintains with a buy rating, and maintains the target price at $65.
Furthermore, according to the comprehensive report, the opinions of $Tandem Diabetes Care (TNDM.US)$'s main analysts recently are as follows:
Tandem Diabetes delivered another solid growth quarter, with an increase in full-year growth guidance to 17%-18%. This performance is largely driven by the continued success of the Mobi launch.
Although Tandem Diabetes has reported its third consecutive quarter of surpassing expectations and raising forecasts, the company's stock performance did not reflect these positive results, which may be due to uncertainties about future growth prospects. It is suggested that the company has completely navigated through its previous challenges and that the fundamental aspects of the business are expected to progressively enhance going forward. Nevertheless, a more cautious stance is being maintained until there is greater assurance in the enduring factors that will drive sales growth.
Concerns regarding Tandem Diabetes' third-quarter revenue outperformance were noted, with contributing factors including timing benefits from U.S. supplies and orders from international distributors. United States pump shipments for the quarter were reported to align closely with expectations.
Here are the latest investment ratings and price targets for $Tandem Diabetes Care (TNDM.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月8日，多家華爾街大行更新了$Tandem Diabetes Care (TNDM.US)$的評級，目標價介於40美元至75美元。
巴克萊銀行分析師Matt Miksic維持買入評級，並將目標價從58美元上調至60美元。
瑞士銀行分析師Danielle Antalffy維持持有評級，維持目標價40美元。
TD Cowen分析師Josh Jennings維持買入評級，維持目標價45美元。
斯迪富分析師Mathew Blackman維持買入評級，維持目標價60美元。
加皇資本市場分析師Shagun Singh Chadha維持買入評級，維持目標價65美元。
此外，綜合報道，$Tandem Diabetes Care (TNDM.US)$近期主要分析師觀點如下：
Tandem Diabetes交付了另一個增長穩固的季度，全年增長預期提高至17％-18％。這一業績主要得益於Mobi發佈持續成功。
儘管Tandem Diabetes已經報告了連續第三個季度超越預期和提升業績預期，但該公司的股票表現並未反映出這些積極結果，這可能是由於對未來增長前景的不確定性。 據建議，該公司已完全克服了以往的挑戰，並預計業務的基本方面將逐步加強。然而，在對將推動銷售增長的持久因素有更大保證之前，將保持更加謹慎的立場。
有關Tandem Diabetes第三季度營收超額表現的擔憂已被注意到，貢獻因素包括來自美國供應商和國際分銷商訂單的時機利益。該季度美國泵裝運量報告顯示與預期基本一致。
以下爲今日8位分析師對$Tandem Diabetes Care (TNDM.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
